Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centro De Ingeniería Genética Y Biotecnología has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is associated with 1 distinct examiner and 1 distinct art unit, resulting in one examination path in the available data.
GOTFREDSON, GAREN is the busiest examiner, with 1 pending matter. Prosecution planning can therefore focus on the individual office action, the claim limitations at issue, and the evidentiary support for the next response. The profile does not identify parallel assignments requiring portfolio-level examiner coordination.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOTFREDSON, GAREN | 1 | 39.9% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268118 | USE OF SYNTHETIC PEPTIDE FOR THE INDUCTION OF ANTITUMOR AND ANTIVIRAL IMMUNITY | GOTFREDSON, GAREN | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268118 | USE OF SYNTHETIC PEPTIDE FOR THE INDUCTION OF ANTITUMOR AND ANTIVIRAL IMMUNITY | GOTFREDSON, GAREN | 12d |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18268118 | USE OF SYNTHETIC PEPTIDE FOR THE INDUCTION OF ANTITUMOR AND ANTIVIRAL IMMUNITY | GOTFREDSON, GAREN | 1619 | §102§103§112 | Non-Final OA | 12d | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentro De Ingeniería Genética Y Biotecnología has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Garen Gotfredson has the most, with 1 of Centro De Ingeniería Genética Y Biotecnología's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
